Rituximab and Belimumab Combination Therapy in PR3 Vasculitis
Status:
Recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
Mechanistic study to assess whether dual B-cell immunotherapy by co-administration of
rituximab and belimumab will result in improvements in biological endpoints, functional
outcomes and clinical status compared to rituximab with placebo.
Phase:
Phase 2
Details
Lead Sponsor:
Rachel Jones
Collaborators:
GlaxoSmithKline Imperial College London Medical Research Council Newcastle University University College, London University of Cambridge University of Glasgow